[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355737-105":59,"doc-detail-355737-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","investigation-of-immunohistochemical-marker-expression-in-breast-cancer-of-varying-severity-and-construction-of-a-predictive-model","Investigation of Immunohistochemical Marker Expression in Breast Cancer of Varying Severity and Construction of a Predictive Model","","Breast cancer severity is examined through clinicopathological and immunohistochemical marker associations, with the goal of informing prognosis and treatment selection. A retrospective cohort of consecutive patients treated from 1 Jan 2019 to 1 May 2024 evaluates candidate predictors including age, BMI, ER, PR, HER2, Ki-67, EGFR, and CK5/6. Axillary lymph-node status is excluded from the primary model and tested in sensitivity analysis. Logistic regression supports nomogram development, internally validated for discrimination and calibration, showing moderate performance and the need for external validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/investigation-of-immunohistochemical-marker-expression-in-breast-cancer-of-varying-severity-and-construction-of-a-predictive-model/355737/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/investigation-of-immunohistochemical-marker-expression-in-breast-cancer-of-varying-severity-and-construction-of-a-predictive-model/355737.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What study objective was addressed regarding breast cancer severity?","Question",{"text":112,"@type":113},"The study evaluated associations between clinicopathological/immunohistochemical markers and stage-defined breast cancer severity at presentation, and it constructed a predictive model.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which predictors were included in the primary and sensitivity models?",{"text":117,"@type":113},"The primary model included age, BMI, ER, PR, HER2, Ki-67, EGFR, and CK5/6, while axillary lymph-node status was excluded and assessed separately in a sensitivity analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about predictors of severe disease?",{"text":121,"@type":113},"Older age was independently associated with severe disease in the revised primary model, while ER and EGFR were not independently significant or only borderline after adjustment. In the sensitivity model, axillary lymph-node metastasis remained the strongest predictor and EGFR positivity remained independently associated with severity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355737,1790718724,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Original Article  \nInvestigation of immunohistochemical marker expression in breast cancer of varying severity and construction of a predictive model  \nZhihao Zhai1,2, Jiuqing Chi1,2, Caixia Li3, Qingjun Li3, Xin Du1,4, Yanuo Li1,2, Xiaowu Wang2  \n1Graduate School of Qinghai University, Xining, China; 2Department of Breast and Thyroid Surgery, The Affiliated Hospital of Qinghai University, Xining, China; 3Department of General Surgery, The Second People’s Hospital of Jiyuan City, Jiyuan, China; 4Department of Ophthalmology, Qinghai Provincial People’s Hospital, Xining, China  \nContributions: (I) Conception and design: All authors; (II) Administrative support: X Wang; (III) Provision of study materials or patients: X Wang; (IV) Collection and assembly of data: Z Zhai; (V) Data analysis and interpretation: Z Zhai; (VI) Manuscript writing: All authors; (VII) Final approval of  \nmanuscript: All authors.  \nCorrespondence to: Xiaowu Wang, MD. Department of Breast and Thyroid Surgery, The Affiliated Hospital of Qinghai University, No. 16, Kunlun  \nRoad, Chengxi District, Xining 810006, [China. Email: wtqba@126.com](China. Email: wtqba@126.com).  \nBackground: Breast cancer is one of the most common malignant tumors in women, associated with high morbidity and mortality; immunohistochemical markers play a critical role in its diagnosis, prognostic evaluation, and treatment selection, and this study aims to evaluate the associations between clinicopathological/immunohistochemical markers and stage-defined breast cancer severity at presentation.  \nMethods: We conducted a retrospective cohort study of consecutive breast cancer patients treated at Qinghai University Affiliated Hospital (1 January 2019–1 May 2024) . Candidate predictors in the primary model included age, body mass index (BMI), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67 antigen (Ki-67), epidermal growth factor receptor (EGFR), and cytokeratin 5/6 (CK5/6). Because axillary lymph-node status is structurally related to stage, it was excluded from the primary model and evaluated only in a sensitivity analysis. Associations with advanced disease were assessed by univariable and multivariable logistic regression. A nomogram was built from independent predictors and  \ninternally validated for discrimination [area under the curve (AUC)] and calibration.  \nResults: In univariable analyses, older age, higher BMI, axillary lymph-node metastasis, HER2 positivity, high Ki-67 expression, and EGFR positivity were associated with higher odds of severe disease, whereas ER positivity was associated with lower odds. In the revised primary multivariable model excluding nodal status, age remained independently associated with severe disease [odds ratio (OR) =1.03; 95% confidence interval (CI): 1.01–1.06; P=0.01], while BMI and EGFR showed borderline positive associations, and ER was no longer independently significant. In the sensitivity model including nodal status, axillary lymphnode metastasis remained the strongest predictor, and EGFR positivity remained independently associated with severity. The primary model showed moderate discrimination after internal validation (apparent  \nAUC =0.713; optimism-corrected AUC =0.679) with acceptable calibration.  \nConclusions: Clinicopathologic and immunohistochemical markers correlate with advanced presentation.  \nIn the revised primary model, age was independently associated with severe disease, while ER and EGFR showed non-significant or borderline associations after adjustment. In the sensitivity analysis, axillary lymphnode metastasis remained the strongest predictor, and EGFR positivity remained independently associated with severity. The nomogram demonstrated moderate discrimination after internal validation and requires  \nexternal validation before clinical application.  \nKeywords: Breast cancer; immunohistochemical markers; breast cancer severity; estrogen receptor (ER);  \nepidermal","cbCaiaqxcgJfvXuT","https://ap.wps.com/l/cbCaiaqxcgJfvXuT","pdf",389705,14,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What study objective was addressed regarding breast cancer severity?\",\"answer\":\"The study evaluated associations between clinicopathological/immunohistochemical markers and stage-defined breast cancer severity at presentation, and it constructed a predictive model.\"},{\"question\":\"Which predictors were included in the primary and sensitivity models?\",\"answer\":\"The primary model included age, BMI, ER, PR, HER2, Ki-67, EGFR, and CK5/6, while axillary lymph-node status was excluded and assessed separately in a sensitivity analysis.\"},{\"question\":\"What were the key findings about predictors of severe disease?\",\"answer\":\"Older age was independently associated with severe disease in the revised primary model, while ER and EGFR were not independently significant or only borderline after adjustment. In the sensitivity model, axillary lymph-node metastasis remained the strongest predictor and EGFR positivity remained independently associated with severity.\"}]","Investigation of Immunohistochemical Marker Expression in Breast Cancer of Varying Severity and Construction of a Predictive Model | PDF",1790120690,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ee82d8cf3fe2718f2b1ccbde457e032.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a348e8e0df511996dc7bc52c7422798.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd0a221a36ae0d0cee83d6eeb8225db3.webp",981,1284,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/258f065d3a2eeedb55f2e4f0c01242fd.webp",980,1283]